KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Capital Expenditures (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Capital Expenditures readings, the most recent being -$1.1 million for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 135.63% to -$1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $608000.0, a N/A change, with the full-year FY2025 number at $608000.0, changed N/A from a year prior.
  • Capital Expenditures hit -$1.1 million in Q4 2025 for Biocryst Pharmaceuticals, down from $597000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.1 million in Q4 2021 to a low of -$1.6 million in Q4 2023.
  • Median Capital Expenditures over the past 5 years was $304500.0 (2021), compared with a mean of $217200.0.
  • Biggest five-year swings in Capital Expenditures: soared 1045.07% in 2021 and later plummeted 406.84% in 2023.
  • Biocryst Pharmaceuticals' Capital Expenditures stood at $1.1 million in 2021, then tumbled by 52.53% to $526000.0 in 2022, then plummeted by 406.84% to -$1.6 million in 2023, then skyrocketed by 72.18% to -$449000.0 in 2024, then crashed by 135.63% to -$1.1 million in 2025.
  • The last three reported values for Capital Expenditures were -$1.1 million (Q4 2025), $597000.0 (Q3 2025), and $926000.0 (Q2 2025) per Business Quant data.